A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients With Incurable Advanced/Metastatic MAGE-A3-Expressing Solid Tumours
Phase of Trial: Phase I/II
Latest Information Update: 26 Oct 2017
At a glance
- Drugs MG1 MA3 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms LANDMARK
- 20 Oct 2017 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018.
- 20 Oct 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Jul 2018.
- 06 Jun 2017 Results (n=41) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History